V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310005189 | 310009257 | 1.65 | 70.1 | Curative (C) | null | 2017-10-02 | Carboplatin + Docetaxel | N | null | 310002123 | CARBOPLATIN + DOCETAXEL |
| 310005190 | 310002381 | 1.81 | null | Palliative (P) | 2016-04-01 | 2017-03-20 | Carbo F | N | N | 310002231 | MVAC |
| 310005191 | 310002381 | 1.52 | 80.3 | Curative (C) | 2014-03-31 | 2014-04-15 | ICON8B TRIAL | 02 | N | 310002231 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 310005192 | 310009258 | 1.68 | 85.3 | Palliative (P) | null | 2017-10-12 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | null | N | 310002273 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 310005193 | 310009258 | 1.69 | 69.8 | Palliative (P) | 2015-06-20 | 2015-02-28 | DABRAFENIB | 1 | N | 310002273 | CARBOPLATIN + RT |
| 310005194 | 310002382 | 1.83 | 77 | Curative (C) | 2017-01-04 | 2017-01-20 | CAP + RT | 02 | N | 310002332 | CARBOPLATIN + PEMETREXED |
| 310005195 | 310002383 | 1.62 | 0 | Palliative (P) | 2018-09-04 | 2018-09-06 | Carboplatin + Liposomal Doxorubicin | N | null | 310002371 | THALIDOMIDE |
| 310005196 | 310002384 | 0 | 72 | Palliative (P) | 2016-05-13 | 2016-05-16 | CAPECITABINE + CISPLATIN + EPIRUBICIN | N | N | 310002555 | BEVACIZUMAB + CARBO |
| 310005197 | 310006989 | 1.58 | 62 | Curative (C) | 2013-08-26 | 2013-08-26 | ICON8B TRIAL | 02 | null | 310002562 | ALEMTUZUMAB |
| 310005198 | 310002385 | 1.68 | null | Neo-adjuvant (N) | 2014-01-22 | 2015-04-27 | Cisplatin + Vinorelbine (PO) | N | N | 310002565 | CARBOPLATIN + VINORELBINE |
| 310005199 | 310002385 | null | null | Palliative (P) | 2014-09-27 | 2014-09-27 | Bevacizumab 7.5mg/kg | 02 | N | 310002565 | ECHELON-2 TRIAL |
| 310005200 | 310009259 | 1.68 | 49.2 | null | 2015-03-15 | 2015-03-16 | Capecitabine + Cisplatin + RT | 02 | N | 310002650 | BEVACIZUMAB |
| 310005201 | 310009259 | 1.67 | null | Adjuvant (A) | 2018-05-05 | 2018-05-01 | DABRAFENIB | 2 | N | 310002650 | CISPLATIN + VINORELBINE + RT |
| 310005202 | 310011099 | 1.73 | 85.5 | Palliative (P) | 2016-01-21 | 2016-01-21 | CARBOPLATIN + RT | N | N | 310002777 | CISPLATIN + VINORELBINE |
| 310005203 | 310002386 | null | 70.5 | Curative (C) | 2015-01-21 | 2015-01-28 | CMV | 02 | N | 310002804 | DA |
| 310005204 | 310002386 | null | 83 | Curative (C) | 2016-10-20 | 2016-11-11 | Alemtuzumab(INTRAVENOUS) | 2 | null | 310002804 | CISPLATIN + FLUOROURACIL + RT |
| 310005205 | 310002386 | 1.74 | 86 | Curative (C) | 2016-12-29 | 2016-12-29 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | 02 | N | 310002804 | CETUXIMAB + RT |
| 310005206 | 310002387 | 1.68 | 88 | Palliative (P) | null | 2016-05-06 | CYCLO + RITUXIMAB + VINCRISTINE | N | null | 310003110 | IDELALISIB + RITUXIMAB |
| 310005207 | 310002388 | 1.69 | 89.6 | Curative (C) | 2019-05-29 | 2019-05-29 | CETUXIMAB + CISPLATIN + FU | N | N | 310003133 | CISPLATIN + FLUOROURACIL + RT |
| 310005208 | 310002388 | 1.89 | 87.6 | Adjuvant (A) | 2017-02-13 | 2017-03-05 | NIVOLUMAB | 02 | N | 310003133 | FCR |
| 310005209 | 310002389 | null | 25.2 | Curative (C) | 1972-09-16 | 2017-10-23 | Cisplatin + Fluorouracil + RT 5day | N | N | 310003169 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310005210 | 310002389 | 1.81 | 77.3 | Curative (C) | 2015-04-17 | 2015-04-22 | POUT TRIAL | null | null | 310003169 | BEVACIZUMAB |
| 310005211 | 310002390 | 1.81 | null | Adjuvant (A) | 2017-10-31 | 2017-11-15 | BEP 5 Day | 02 | N | 310003186 | ECHELON 1 TRIAL |
| 310005212 | 310002391 | 1.7 | null | Disease modification (D) | 2017-10-30 | 2017-11-24 | Bevacizumab 15mg/kg | N | Y | 310003191 | BEVACIZUMAB + TEMOZOLOMIDE |
| 310005213 | 310002391 | 1.73 | 75 | Curative (C) | 2017-11-22 | 2017-11-22 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 310003191 | RUXOLITINIB |
| 310005214 | 310002392 | 1.72 | 75.9 | Curative (C) | 2013-05-09 | 2013-05-09 | OCTREOTIDE | 02 | N | 310003259 | ALEMTUZUMAB |
| 310005215 | 310006995 | 0 | 65 | Curative (C) | 2018-10-06 | 2018-10-08 | Bendamustine+Rituximab (1st Course) | 02 | null | 310003341 | CETUXIMAB + RT |
| 310005216 | 310002393 | 1.68 | 59.7 | Palliative (P) | 2018-08-08 | 2018-08-28 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | Y | N | 310003357 | CAPECITABINE + CARBOPLATIN |
| 310005217 | 310002393 | 1.77 | 70.3 | Curative (C) | 2014-01-27 | 2014-01-27 | OCTREOTIDE | 02 | N | 310003357 | IVE |
| 310005218 | 310002393 | 1.64 | 72.5 | null | 2017-07-26 | 2017-07-27 | Cisplatin + Pemetrexed | N | N | 310003357 | DABRAFENIB |
| 310005219 | 310002393 | 1.86 | null | Palliative (P) | 2016-12-30 | 2016-12-30 | CVP R | 02 | N | 310003357 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 310005220 | 310002394 | null | null | Palliative (P) | 2016-01-23 | 2016-01-31 | Cisplatin + Pemetrexed | 02 | N | 310003423 | PEG INTERFERON |
| 310005221 | 310002394 | 1.7 | 75.2 | Curative (C) | 2017-12-16 | 2018-09-16 | IVE + METHOTREXATE | Y | N | 310003423 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 310005222 | 310002395 | 1.54 | null | Curative (C) | 2017-04-23 | 2017-04-24 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 310003470 | BORTEZOMIB |
| 310005223 | 310002396 | null | 55 | Curative (C) | 2018-06-17 | 2018-06-20 | IVE | 2 | N | 310003532 | ERLOTINIB |
| 310005224 | 310002397 | 1.6 | null | Adjuvant (A) | 2017-12-20 | 2017-12-25 | FEC 100 | 2 | Y | 310003549 | CAPECITABINE + MITOMYCIN + RT |
| 310005225 | 310002398 | 1.47 | 61 | Curative (C) | 2018-09-08 | 2018-09-26 | Sunitinib | 02 | Y | 310003601 | CVP R + GEMCITABINE |
| 310005226 | 310002399 | 1.53 | 48.5 | Curative (C) | 2015-12-27 | 2017-04-22 | IVE | 02 | N | 310003624 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 310005227 | 310002400 | 1.65 | 70.3 | Palliative (P) | 2015-03-24 | 2015-03-27 | Carboplatin + Liposomal Doxorubicin | N | N | 310003625 | DABRAFENIB |
| 310005228 | 310002401 | null | 92.2 | Palliative (P) | 2015-05-08 | 2015-05-13 | Sunitinib | null | N | 310003649 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 310005229 | 310002401 | 1.63 | 0 | Curative (C) | 2016-09-20 | 2016-09-21 | CAPECITABINE + CARBOPLATIN | 02 | N | 310003649 | CISPLATIN + PEMETREXED |
| 310005230 | 310009262 | 1.7 | 72.5 | Curative (C) | null | 2016-12-29 | IVE | Y | N | 310003672 | DABRAFENIB |
| 310005231 | 310002402 | 1.54 | 62 | Palliative (P) | 2016-03-09 | 2016-06-08 | DABRAFENIB | 2 | N | 310003688 | DOXORUBICIN + OLARATUMAB |
| 310005232 | 310002403 | 1.76 | 93.099 | Palliative (P) | 2014-03-18 | 2014-03-18 | Everolimus 10mg | 02 | N | 310003701 | IFOSFAMIDE |
| 310005233 | 310002404 | 0 | 148.6 | Adjuvant (A) | 2016-12-10 | 2016-12-12 | R GDP | 02 | N | 310003726 | DOXORUBICIN + OLARATUMAB |
| 310005234 | 310002405 | 1.81 | 84.5 | Disease modification (D) | 2014-08-04 | 2014-08-04 | Cetuximab + Radiotherapy Load | Y | N | 310003729 | CISPLATIN + VINORELBINE + RT |
| 310005235 | 310002405 | 1.54 | 67.2 | Palliative (P) | 2017-03-05 | 2017-03-06 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 310003729 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE |
| 310005236 | 310002406 | 1.71 | null | Palliative (P) | 2015-08-23 | 2015-09-07 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | N | N | 310003753 | UKALL2011 |
| 310005237 | 310002407 | 1.54 | 68.7 | Palliative (P) | 2017-07-26 | 2017-07-26 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 310003761 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310005238 | 310002408 | 1.64 | 52 | Palliative (P) | 2017-07-22 | 2017-07-23 | CAPECITABINE + CARBOPLATIN | N | N | 310003774 | IVE + METHOTREXATE |